Rituximab biosimilar(iBio Inc.)

N/A

Report date: 2025/03/07 17:34:24

Base Information

Drug NameRituximab biosimilar(iBio Inc.)

Drug Alias NameN/A

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants

TargetsNot applicable

Therapy Area/IndicationsAutoimmune Diseases of the Nervous SystemNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesIbio Inc

China Registration ClassN/A

Active CompaniesIbio Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune Diseases of the Nervous SystemNeoplasms

Inactive IndicationsN/A

ATC CodeN/A